CrystalGenomics Invites Co Ltd
083790
Company Profile
Business description
CrystalGenomics Invites Co Ltd Formerly CrystalGenomics Inc is one of the leading biopharmaceutical company in Korea. The company is mainly engaged in the research and development and new drug development. It develops innovative new drug development projects such as eradication antibiotics and molecular targeted anticancer drugs. It focuses on arthritic medicines and antibiotics which kill resistant bacteria. It also offers medicines for cancer, obesity, asthma, and diabetes.
Contact
5F, A-dong, Korea Bio Park
694-1, Sampyeong-dong, Bundang-gu
Seongnam-siGyeonggi463-400
KORT: +82 316282700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
78
Stocks News & Analysis
stocks
Is this ASX share a long-term buy?
Current operating conditions are challenging but over the long-term prospects are better.
stocks
Why Guzman and Reece's share reversals have a lot in common
Investors must weigh exciting growth stories against competitive dynamics and the price they are being asked to pay.
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
Watching the data centre business and the debate around it, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,477.30 | 20.70 | -0.24% |
| CAC 40 | 8,143.92 | 92.85 | 1.15% |
| DAX 40 | 22,794.11 | 383.84 | 1.71% |
| Dow JONES (US) | 43,412.50 | 208.66 | -0.48% |
| FTSE 100 | 8,731.46 | 62.79 | 0.72% |
| HKSE | 23,787.93 | 753.91 | 3.27% |
| NASDAQ | 19,089.08 | 62.69 | 0.33% |
| Nikkei 225 | 38,142.37 | 95.42 | -0.25% |
| NZX 50 Index | 12,452.46 | 145.19 | 1.18% |
| S&P 500 | 5,957.19 | 1.94 | 0.03% |
| S&P/ASX 200 | 8,240.70 | 11.20 | -0.14% |
| SSE Composite Index | 3,380.21 | 34.17 | 1.02% |